Feeds:
Posts
Comments

Search Results for 'Nebivolol'

FDA Advisory votes against approving Actavis nebivolol/valsartan combo – The Pharma Letter

Posted in Uncategorized on September 12, 2014| Leave a Comment »


Bidness ETC FDA Advisory votes against approving Actavis nebivolol/valsartan combo The Pharma Letter Nebivolol (marketed in the USA as Bystolic by Actavis subsidiary Forest Labs) is indicated for the treatment of hypertension and is effective at… Source: http://www.thepharmaletter.com See on Scoop.it – Cardiotoxicity

Read Full Post »

Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation

Posted in Biological Networks, Gene Regulation and Evolution, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Frontiers in Cardiology and Cardiovascular Disorders, Health Economics and Outcomes Research, HTN, Origins of Cardiovascular Disease, Pharmaceutical Analytics, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacotherapy of Cardiovascular Disease, Population Health Management, Genetics & Pharmaceutical, Resident-cell-based, tagged , , , , , , , , , on July 16, 2012| 26 Comments »


Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial  Progenitor Cells Endogenous Augmentation Curator: Aviva Lev-Ari, PhD, RN   Bystolic’s generic Nebivolol – FDA approved for Treatment of Hypertension since 2008 – Pharmacological agent hypothesized to have positive effect on circulating Endothelial  Progenitor Cells (cEPCs) endogenous augmentation: Low number of cEPCs found to be associated with […]

Read Full Post »

COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response

Posted in Coronavirus Gene Expression, COVID-19, Population Health Management, Genetics & Pharmaceutical, SARS-CoV-2, Serology tests for coronavirus antibodies, Treatment Protocols for COVID-19, Vaccinology, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 29, 2020| Leave a Comment »


COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response Curator: Aviva Lev-Ari, PhD, RN   On 5/26/2020 LPBI organized a Symposium on New Therapeutics for COVID-19 AGENDA included presentations by: Dr. Raphael […]

Read Full Post »

Clinical Trial for the Use of Nitric Oxide to Treat Severe COVID-19 Infection

Posted in COVID-19, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Nitric Oxide in Health and Disease, Population Health Management, Population Health Management, Genetics & Pharmaceutical, SARS-CoV-2, Virus Infective Acute Respiratory Syndrome: SARS-CoV on April 14, 2020| 2 Comments »


Clinical Trial for the Use of Nitric Oxide to Treat Severe COVID-19 Infection Reporter and Curator: Aviva Lev-Ari, PhD, RN   UPDATED 5/26/2020 Virology . 2009 Dec 5;395(1):1-9. doi: 10.1016/j.virol.2009.09.007. Epub 2009 Oct 1. Dual Effect of Nitric Oxide on SARS-CoV Replication: Viral RNA Production and Palmitoylation of the S Protein Are Affected Sara Akerström1, Vithiagaran Gunalan, Choong Tat […]

Read Full Post »

2021 LPBI Plan for IT Projects & Research Projects – LPBI’s TASKS for Research Assistants & Associates

Posted in on May 2, 2019|


2021 LPBI Plan for IT Projects & Research Projects – LPBI’s TASKS for Research Assistants & Associates UPDATED ON 7/16/2021 Project #1: INDEXING all Content for Blockchain Migration per a schema designed by a Vendor in the blookchain space Project #2: How to start a New Website connected to PharmaceuticalIntelligence.com Spanish BioMed e-Series – New […]

Read Full Post »

Top Articles by Number of e-Readers for All Days ending 2020-06-02

Posted in on February 17, 2019|


UPDATED on 6/9/2020 Top Posts for all days ending 2020-06-02 (Summarized) Top Posts for all days ending 2020-06-02 (Summarized)               All Time       Title Views Author Name Type of Article Home page / Archives 676,690 Internet Access Tabulation Is the Warburg Effect the Cause or the Effect […]

Read Full Post »

Dynamic Contents for LPBI Group’s PowerPoint Presentation

Posted in on February 17, 2019|


Dynamic Contents for LPBI Group’s PowerPoint Presentation   The source material used in the creation of LPBI Group’s PowerPoint Presentation is from Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/ WORK-in-PROGRESS   Challenges and Opportunities for […]

Read Full Post »

Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

Posted in Academic Publishing, Big Data & Analytics, Curation, Curation methodology, De novo synthesis, Dialectic, Discovery process, Evolutionary cognition, Experimental validation, Explanatory, Historical relevance, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Open Access Journals, Scientific Publishing, Scientist: Career considerations, Technology Advance Assessment of, Theoretic convergence on January 30, 2019| Leave a Comment »


Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com   Reporter: Aviva Lev-Ari, PhD, RN   Expert, Author, Writer’s Initials Name & Bio Roles @LPBI Group LHB Larry Bernstein, MD, FACP,   Member of the Board Expert, Author, Writer – All Specialties of Medicine & Pathology Content Consultant to Series B,C,D,E Editor, Series […]

Read Full Post »

Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

Posted in LPBI Group Founder - Aviva Lev-Ari on October 21, 2018| Leave a Comment »


Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN   March 31, 2018 Yidan Prize for Education Development recognizes innovative ideas that tackle pressing challenges in the field of education. Nomination for recognition as means in tackling challenges […]

Read Full Post »

Data Science is the Greatest Science! It is the Greatest Science for Women, as well

Posted in Big Data & Analytics, Data Science, Scientist: Career considerations, Women in Life Sciences on March 12, 2018| 1 Comment »


Data Science is the Greatest Science! It is the Greatest Science for Women, as well Curator: Aviva Lev-Ari, PhD, RN   UPDATED ON 3/2/2018 The Growing Influence of Analytics on the C-Suite     This curation has three parts: Part 1: Account of a Data Scientist, Aviva Lev-Ari, PhD – worked in Data Science, 1976-2005 […]

Read Full Post »

Next »